You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Complex 3-Dimensional in vitro Human Skin Tissue Models for Scleroderma

    SBC: CELDARA MEDICAL, LLC            Topic: NIAMS

    PROJECT SUMMARY Sclerodermasystemic sclerosisSScis an autoimmune disease of unknown etiology that is characterized by vascular dysfunctionfibrosisand inflammationOne in three patients dies withinyears of diagnosisgiving SSc the highest case fatality rate of any systemic autoimmune diseaseA lack of biologically relevant SSc disease models has created a critical unmet need for more efficient preclin ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Novel therapeutic approach in treatment of glioblastoma using sustained delivery of Connxin43 carboxy-terminal peptide encapsulated in biodegradable nanoparticles in combination with temozolomide

    SBC: FirstString Research, Inc            Topic: 102

    PROJECT SUMMARY Glioblastoma (GBM) is an incurable cancer even with aggressive therapies such as surgical resection followed by radiotherapy and chemotherapy using temozolomide (TMZ). Efforts to improve surgical resection or the efficacy of irradiation are limited by the potential damage these interventions cause to the brain. In contrast, sensitizing GBM to TMZ is an appealing strategy because TM ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Targeting leukocyte metabolism to treat human autoimmune disease

    SBC: Immunext, Inc.            Topic: R

    ImmuNext has defined an anti-MCT1 monoclonal antibody (mAb) that will be developed for the treatment of human autoimmune disease. The membrane monocarboxylate nutrient transporter SLC16A1 (MCT1) is a multi-pass transmembrane protein responsible for the facilitated transport of critical metabolites, including products of glycolysis: lactate, pyruvate and ketones. Our strong preliminary data support ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Administrative Supplement to Promote Diversity in Research and Development Small Businesses

    SBC: NEUROENE THERAPEUTICS INC            Topic: NINDS

    Abstract Neuroene Therapeutics is a biotech company established to develop and commercialize safe effective therapies for epilepsyinpeople develop epilepsy in their lifetimehowever the currently available anti epileptic drugsAEDshave several issues and liabilities that leave unmet market needssuch asnot controlling seizures forof patients with epilepsycurrent AEDs only treat the symptoms of epilep ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. STEM Interactive Digital Tool to Educate and Promote Hearing Health and Science for 4th to 7th Grade

    SBC: CREARE LLC            Topic: 500

    PROJECT SUMMARY ABSTRACT The National Research Council recognizes that serious computer games can support new inquiry based approaches to science instructionproviding virtual laboratories or field learning experiences that overcome practical and logistical constraints to student investigationsWith the nationally recognized need to encourage and enhance education in the ScienceTechnologyEngineering ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: LEUKOGENE THERAPEUTICS INC            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Adaptable Pediatric Neurocognitive Assessment

    SBC: CREARE LLC            Topic: 103

    PROJECT SUMMARY ABSTRACTMillions of children around the globe are afflicted with conditions that can alter neuropsychological developmentincluding human immunodeficiency virusHIVtraumatic brain injuryTBIcerebral malariaand a host of other developmental and acquired diseases and disordersEarly assessment and intervention are critical in overcoming cognitive and developmental deficiencies and are in ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government